ERBB2 and adenocarcinoma: A novel anti-HER2 monoclonal antibody, Margetuximab, was combined with Pembrolizumab in a single arm phase Ib/II trial in patients with previously treated HER2+ adenocarcinoma of the gastroesophageal junction and stomach (n = 95 patients).